FABIO E SU-DIAZ

Allopathic & Osteopathic Physicians|Family Medicine POMPANO BEACH, FL NPI 1841305752

General Payments — all program years on this page

$1,299.44

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 73
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $378.61 across 21 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $378.6121

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $182.9911
Amgen Inc. $143.737
Esperion Therapeutics, Inc. $19.681
Abbott Laboratories $16.521
Lilly USA, LLC $15.691

By program year

Program yearAmountRecords
2018 $147.5811
2019 $52.704
2020 $17.841
2021 $32.972
2022 $399.8720
2023 $269.8714
2024 $378.6121

Records — PY2024 (21)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096610246 Novo Nordisk Inc $23.33 08/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096618334 Novo Nordisk Inc $7.36 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096654667 Novo Nordisk Inc $17.10 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096681697 Novo Nordisk Inc $23.34 12/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096682845 Novo Nordisk Inc $9.80 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096865503 Novo Nordisk Inc $18.36 02/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096921130 Novo Nordisk Inc $13.15 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096954777 Novo Nordisk Inc $19.17 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097109866 Novo Nordisk Inc $13.27 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097153654 Novo Nordisk Inc $18.11 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097438229 Novo Nordisk Inc $20.00 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393594 Amgen Inc. $22.57 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393596 Amgen Inc. $25.40 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393598 Amgen Inc. $23.78 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393600 Amgen Inc. $21.21 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393602 Amgen Inc. $17.30 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393604 Amgen Inc. $18.41 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117393606 Amgen Inc. $15.06 11/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125298831 Abbott Laboratories $16.52 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1129456878 Esperion Therapeutics, Inc. $19.68 09/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136174424 Lilly USA, LLC $15.69 10/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.